AMENDMENT 1 TO THE LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONELicense, Development, Commercialization and Supply Agreement • March 11th, 2016 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amendment 1 is entered into as of 18 November 2015 (the “Effective Date”) by and between Sucampo AG, a corporation organized under the laws of Switzerland with principal offices at Baarerstrasse 22, CH-6300, Zug, Switzerland (“Sucampo”) and Takeda Pharmaceuticals International AG (formerly registered as Takeda Pharmaceuticals International GmbH), a corporation organized under the laws of Switzerland with principal offices at Thurgauerstrasse 130, 8152 Glattpark-Opfikon, Zurich, Switzerland (“Takeda”). Each of Takeda and Sucampo is referred to individually herein as a “Party” and collectively as the “Parties”.
LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR PEOPLE’S REPUBLIC OF CHINALicense, Development, Commercialization and Supply Agreement • August 5th, 2015 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • Hong Kong
This LICENSE, DEVELOPMENT, COMMERCIALIZATION, AND SUPPLY AGREEMENT FOR LUBIPROSTONE FOR PEOPLE’S REPUBLIC OF CHINA (“Agreement”) is entered into as of May 5, 2015, by and between Sucampo AG, a corporation organized under the laws of Switzerland with principal offices at Baarerstrasse 22, CH-6300, Zug, Switzerland (“Sucampo”) and Harbin Gloria Pharmaceuticals Co., Ltd. ("Gloria"), a corporation organized under the laws of Peoples Republic of China with principal offices at #28 Ronghui Garden, Yuhua Road, Konggang Airport Development Zone B, Shunyi District, Beijing 101318, People’s Republic of China (“Gloria”). Each of Gloria and Sucampo is sometimes referred to individually herein as a “Party” and collectively as the “Parties”.
LICENSE, DEVELOPMENT, COMMERCIALIZATION AND SUPPLY AGREEMENT FOR LUBIPROSTONE by and between Takeda Pharmaceuticals International GmbH and SUCAMPO AG Dated as of October 17, 2014License, Development, Commercialization and Supply Agreement • March 9th, 2015 • Sucampo Pharmaceuticals, Inc. • Pharmaceutical preparations • New York
